Will this be the end of the anticoagulation clinic for patients with atrial fibrillation?

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 5, Issue 5, 2005, Pages 405-408

  Mitchell, A R J ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Atrial fibrillation; Direct thrombin inhibitors; Thromboembolism; Warfarin; Ximelagatran

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; IDRAPARINUX; LIVER ENZYME; MELAGATRAN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

AGING; ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HEART ATRIUM FIBRILLATION; HOSPITALIZATION; HUMAN; LIVER DYSFUNCTION; LIVER FUNCTION; MORBIDITY; MORTALITY; REVIEW; RISK REDUCTION; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANTICOAGULANTS; ATRIAL FIBRILLATION; AZETIDINES; BENZYLAMINES; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS; HUMANS; RANDOMIZED CONTROLLED TRIALS; THROMBIN; WARFARIN;

EID: 27744497499     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800605774370344     Document Type: Review

References (36)

1. Stewart, S., Hart, C.L., Hole, D.J., McMurray, J.J. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med. 2002, 113(5), 359-364.
2. Hart, R.G., Benavente, O., McBride, R., Pearce, L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 1999, 131(7), 492-501.
3. Petersen, P., Boysen, G., Godtfredsen, J., Andersen, E.D., Andersen, B. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989, 1(8631), 175-179.
4. Stroke Prevention in Atrial Fibrillation Study. Final results. Circulation 1991, 84(2), 527-539.
5. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N. Engl. J. Med 1990, 323(22), 1505-1511.
6. Connolly, S.J., Laupacis, A., Gent, M., Roberts, R.S., Cairns, J.A., Joyner, C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J. Am. Coll. Cardiol. 1991, 18(2), 349-55.
7. Ezekowitz, M.D., Bridgers, S.L., James, K.E., Carliner, N.H., Colling, C.L., Gornick, C.C., Krause-Steinrauf, H., Kurtzke, J.F., Nazarian, S.M., Radford, M.J. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N. Engl. J. Med. 1992, 327(20), 1406-1412.
8. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993, 342(8882), 1255-1262.
9. Hart, R.G., Benavente, O., McBride, R., Pearce, L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann. Intern. Med. 1999, 131(7), 492-501.
10. Diener, H.C., Cunha, L., Forbes, C., Sivenius, J., Smets, P., Lowenthal, A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 1996, 143(1-2), 1-13.
11. Posada, I.S., Barriales, V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. Am. Heart J. 1999, 138(1 Pt. 1), 137-143.
12. Benavente, O., Hart, R., Koudstaal, P., Laupacis, A., McBride, R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. Cochrane. Database. Syst. Rev. 2000(2), CD001925.
13. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343(8899), 687-691.
14. Gullov, A.L., Koefoed, B.G., Petersen, P., Pedersen, T.S., Andersen, E.D., Godtfredsen, J., Boysen, G. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch. Intern. Med. 1998, 158(14), 1513-1521.
15. Hellemons, B.S., Langenberg, M., Lodder, J., Vermeer, F., Schouten, H.J., Lemmens, T., van Ree, J.W., Knottnerus, J.A. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ 1999, 319(7215), 958-964.
16. Olsson, S.B. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet 2003, 362(9397), 1691-1698.
17. Albers, G.W. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am. J. Manag. Care 2004, 10(14 Suppl.), S462-S469.
18. Fang, M.C., Stafford, R.S., Ruskin, J.N., Singer, D.E. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch. Intern. Med. 2004, 164(1), 55-60.
19. Sudlow, M., Thomson, R., Thwaites, B., Rodgers, H., Kenny, R.A. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998, 352(9135), 1167-1171.
20. Artang, R., Vidaillet, H. Alternatives to warfarin for thromboembolism prophylaxis in nonrheumatic atrial fibrillation. J. Interv. Card. Electrophysiol. 2004, 10 Suppl. 1, 33-44.
21. McAnulty, J.H. Barriers to the use of warfarin: potential solutions. J. Interv. Card. Electrophysiol 2004, 10 Suppl. 1, 17-20.
22. Perez, I., Melbourn, A., Kalra, L. Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart 1999, 82(5), 570-574.
23. Hylek, E.M., Go, A.S., Chang, Y., Jensvold, N.G., Henault, L.E., Selby, J.V., Singer, D.E. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N. Engl. J. Med. 2003, 349(11), 1019-1026.
24. Desbiens, N.A. Deciding on anticoagulating the oldest old with atrial fibrillation: insights from cost-effectiveness analysis. J. Am. Geriatr. Soc. 2002, 50(5), 863-869.
25. Hopfner, R. Ximelagatran (AstraZeneca). Curr. Opin. Investig. Drugs 2002, 3(2), 246-251.
26. Petersen, P., Grind, M., Adler, J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. J. Am. Coll. Cardiol 2003, 41(9), 1445-1451.
27. Halperin, J. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am. Heart J. 2003, 146(3), 431-438.
28. Albers, G.W., Diener, H.C., Frison, L., Grind, M., Nevinson, M., Partridge, S., Halperin, J.L., Horrow, J., Olsson, S.B., Petersen, P., Vahanian, A. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005, 293(6), 690-698.
29. Albers, G. W. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials. Am. J. Manag. Care 2004, 10(14 Suppl.), S462-S469.
30. O'Brien, C.L., Gage, B.F. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation. JAMA 2005, 293(6), 699-706.
31. Nutescu, E.A., Pickard, A.S., Blackburn, J.C., Wittkowsky, A.K., Ansell, J., Schumock, G.T. Impact of oral direct thrombin inhibitors on anticoagulation clinics. Pharmacotherapy 2004, 24(9), 1204-1212.
32. Cooper, H.A. Trials of newer approaches to anticoagulation in atrial fibrillation. J. Interv. Card. Electrophysiol 2004, 10 Suppl. 1, 27-31.
33. Gustafsson, D. Oral direct thrombin inhibitors in clinical development. J. Intern. Med. 2003, 254(4), 322-34.
34. Mungall, D. BIBR-1048 Boehringer Ingelheim. Curr. Opin. Investig. Drugs 2002, 3(6), 905-7.
35. Reiter, M., Bucek, R.A., Koca, N., Heger, J., Minar, E. Idraparinux and liver enzymes: observations from the PERSIST trial. Blood Coagul. Fibrinolysis 2003, 14(1), 61-5.
36. Lorenzoni, R., Lazzerini, G., Cocci, F., De Caterina, R. Short-term prevention of thromboembolic complications in patients with atrial fibrillation with aspirin plus clopidogrel: the Clopidogrel-Aspirin Atrial Fibrillation (CLAAF) pilot study. Am. Heart J. 2004, 148(1), e6.